The HPTA Axis: Why Recovery Matters
The hypothalamic-pituitary-testicular axis (HPTA) is the hormonal cascade that controls endogenous testosterone production. It begins at the hypothalamus (releases GnRH in pulses), signals the anterior pituitary (releases LH and FSH), and culminates at the Leydig cells in the testes (produce testosterone). Exogenous androgens shut this axis down completely through negative feedback — the brain detects supraphysiological testosterone and stops producing GnRH.
Post Cycle Therapy (PCT) aims to restart this cascade after anabolic steroid or SARM use. The speed and completeness of HPTA recovery determines whether the user experiences sustained hypogonadism, muscle loss, depression, and sexual dysfunction in the post-cycle period.
HCG: The Traditional PCT Tool
Human Chorionic Gonadotropin (HCG) is structurally identical to luteinizing hormone (LH). It bypasses the hypothalamus and pituitary entirely, directly stimulating Leydig cells to produce testosterone. This restores serum testosterone levels rapidly but does NOT restart the brain's signaling — it's the hormonal equivalent of hot-wiring a car instead of fixing the ignition.
HCG limitations: dramatically increases intra-testicular aromatase activity, causing estrogen spikes that often require an aromatase inhibitor (AI). Prolonged HCG use can desensitize Leydig cells, paradoxically worsening recovery. Typical PCT dose: 1,000-2,000 IU every other day for 2-3 weeks.
Kisspeptin-10: Upstream HPTA Restart
Kisspeptin-10 acts at the very top of the HPTA axis. It binds to GPR54 (KISS1R) receptors on GnRH neurons in the arcuate nucleus of the hypothalamus, triggering pulsatile GnRH release. This cascades naturally: GnRH → LH + FSH → testosterone. Every step of the endogenous cascade is activated organically.
The critical advantage: because Kisspeptin restarts the brain's own pulsatile GnRH secretion, LH release is physiological and pulsatile — not the constant, supraphysiological stimulation HCG produces. This means dramatically less aromatase upregulation, no Leydig cell desensitization risk, and simultaneous FSH recovery (which HCG alone does not address).
Dosing: 100-300 mcg subcutaneously, 1-2 times daily. Due to its very short half-life (minutes), some advanced protocols use 2-3 daily injections to maintain pulsatile GnRH activation throughout the day.
Head-to-Head Comparison
Speed of testosterone recovery: HCG is faster (24-48 hours to measurable increase). Kisspeptin requires 7-10 days to fully restart the axis but produces a more robust, self-sustaining recovery.
Estrogen management: HCG nearly always requires concurrent AI administration. Kisspeptin rarely requires an AI because the physiological LH pulsatility it produces does not upregulate aromatase to the same degree.
Fertility preservation: Kisspeptin restores both LH and FSH, preserving spermatogenesis. HCG restores only LH-mediated testosterone — FSH must recover independently, which can take months.
Cost: HCG is significantly cheaper and more widely available. Kisspeptin-10 requires peptide sourcing and careful reconstitution.